138 related articles for article (PubMed ID: 17362443)
21. [A case of valsartan-induced pneumonitis with marked elevation of serum KL-6].
Takakura A; Kubota M; Otani S; Katono K; Yamamoto M; Masuda N
Nihon Kokyuki Gakkai Zasshi; 2011 Jul; 49(7):523-7. PubMed ID: 21842690
[TBL] [Abstract][Full Text] [Related]
22. Blepharospasm and apraxia of eyelid opening in lithium intoxication.
Micheli F; Cersósimo G; Scorticati MC; Ledesma D; Molinos J
Clin Neuropharmacol; 1999; 22(3):176-9. PubMed ID: 10367183
[TBL] [Abstract][Full Text] [Related]
23. Valsartan inefficacy or ill-effects of concomitant medications!
Bangalore S; Messerli FH
Am J Cardiol; 2010 Aug; 106(4):602-3. PubMed ID: 20691326
[No Abstract] [Full Text] [Related]
24. Linear lichenoid drug eruption induced by valsartan.
Gencoglan G; Ceylan C; Kazandi AC
Clin Exp Dermatol; 2009 Oct; 34(7):e334-5. PubMed ID: 19456765
[No Abstract] [Full Text] [Related]
25. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex.
Bork K; Dewald G
Am J Med; 2004 May; 116(9):644-5. PubMed ID: 15093766
[No Abstract] [Full Text] [Related]
26. Recurrent small intestinal ileus secondary to valsartan treatment.
Saadi T; Brun R; Chowers Y; Baruch Y; Waterman M
J Clin Gastroenterol; 2014; 48(5):462-3. PubMed ID: 24296424
[No Abstract] [Full Text] [Related]
27. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
28. VALUE: analysis of results.
Sever P
Lancet; 2004 Sep 11-17; 364(9438):933-4; author reply 935. PubMed ID: 15364180
[No Abstract] [Full Text] [Related]
29. Valsartan, captopril, or both in myocardial infarction.
Jorde UP
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
[No Abstract] [Full Text] [Related]
30. Valsartan, captopril, or both in myocardial infarction.
Moshenyat R; Kupfer Y; Tessler S
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
[No Abstract] [Full Text] [Related]
31. Ask the doctor. I read that angiotensin-receptor blockers cause cancer. I take one (Diovan) for my blood pressure. Should I stop?
Lee T
Harv Heart Lett; 2010 Dec; 21(4):8. PubMed ID: 21218537
[No Abstract] [Full Text] [Related]
32. [Creatively revised quotation on sale arguments concerning Diovan (valsartan].
Andersen SE; Pedersen ST
Ugeskr Laeger; 2000 Nov; 162(47):6430. PubMed ID: 11116460
[No Abstract] [Full Text] [Related]
33. Angioedema due to valsartan.
Martínez Alonso JC; Domínguez Ortega FJ; Méndez Alcalde J; Fuentes Gonzalo MJ
Allergy; 2003 Apr; 58(4):367. PubMed ID: 12708991
[No Abstract] [Full Text] [Related]
34. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
35. [Acute hepatitis induced by valsartan].
Reñé JM; Buenestado J; Sesé E; Miñana JM
Med Clin (Barc); 2001 Nov; 117(16):637-8. PubMed ID: 11714476
[No Abstract] [Full Text] [Related]
36. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
37. Safety concerns of angiotensin II receptor blockers in preschool children.
Tullus K
Arch Dis Child; 2011 Sep; 96(9):881-2. PubMed ID: 21690106
[TBL] [Abstract][Full Text] [Related]
38. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
Hollenberg NK; Parving HH; Viberti G; Remuzzi G; Ritter S; Zelenkofske S; Kandra A; Daley WL; Rocha R
J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658
[TBL] [Abstract][Full Text] [Related]
39. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
Kondrack R; Mohiuddin S
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1125-34. PubMed ID: 19689218
[TBL] [Abstract][Full Text] [Related]
40. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
Schmieder RE; Kjeldsen SE; Julius S; McInnes GT; Zanchetti A; Hua TA;
J Hypertens; 2008 Mar; 26(3):403-11. PubMed ID: 18300848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
